Literature DB >> 27489798

Prospects for dengue vaccines for travelers.

Sl-Ki Lim1, Yong Seok Lee1, Suk Namkung1, Jacqueline K Lim1, In-Kyu Yoon1.   

Abstract

Travel-acquired dengue cases have been increasing as the overall global dengue burden has expanded. In Korea, imported dengue cases have been reported since 2000 when it first became a notifiable disease. During the first four months of 2016, three times more dengue cases were reported in Korea than during the same period the previous year. A safe and efficacious vaccine for travelers would be beneficial to prevent dengue disease in individual travelers and potentially decrease the risk of virus spread to non-endemic areas. Here, we summarize the characteristics of dengue vaccines for travelers and review dengue vaccines currently licensed or in clinical development.

Entities:  

Keywords:  Dengue; Dengue vaccines; Travel

Year:  2016        PMID： 27489798      PMCID： PMC4969283          DOI： 10.7774/cevr.2016.5.2.89

Source DB:  PubMed          Journal:  Clin Exp Vaccine Res        ISSN： 2287-3651


  58 in total

1.  Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys.

Authors:  Kanakatte Raviprakash; Dan Ewing; Monika Simmons; Kevin R Porter; Trevor R Jones; Curtis G Hayes; Richard Stout; Gerald S Murphy
Journal:  Virology       Date:  2003-10-25       Impact factor: 3.616

2.  Autochthonous dengue fever in Croatia, August-September 2010.

Authors:  I Gjenero-Margan; B Aleraj; D Krajcar; V Lesnikar; A Klobučar; I Pem-Novosel; S Kurečić-Filipović; S Komparak; R Martić; S Duričić; L Betica-Radić; J Okmadžić; T Vilibić-Čavlek; A Babić-Erceg; B Turković; T Avsić-Županc; I Radić; M Ljubić; K Sarac; N Benić; G Mlinarić-Galinović
Journal:  Euro Surveill       Date:  2011-03-03

Review 3.  The dengue vaccine pipeline: Implications for the future of dengue control.

Authors:  Lauren M Schwartz; M Elizabeth Halloran; Anna P Durbin; Ira M Longini
Journal:  Vaccine       Date:  2015-05-16       Impact factor: 3.641

Review 4.  Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Alexander C Schmidt; Stephen S Whitehead
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

5.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2013-01-17       Impact factor: 5.226

6.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Authors:  Sri Rezeki Hadinegoro; Jose Luis Arredondo-García; Maria Rosario Capeding; Carmen Deseda; Tawee Chotpitayasunondh; Reynaldo Dietze; H I Hj Muhammad Ismail; Humberto Reynales; Kriengsak Limkittikul; Doris Maribel Rivera-Medina; Huu Ngoc Tran; Alain Bouckenooghe; Danaya Chansinghakul; Margarita Cortés; Karen Fanouillere; Remi Forrat; Carina Frago; Sophia Gailhardou; Nicholas Jackson; Fernando Noriega; Eric Plennevaux; T Anh Wartel; Betzana Zambrano; Melanie Saville
Journal:  N Engl J Med       Date:  2015-07-27       Impact factor: 91.245

Review 7.  Dengue virus vaccine development.

Authors:  Lauren E Yauch; Sujan Shresta
Journal:  Adv Virus Res       Date:  2014       Impact factor: 9.937

Review 8.  Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?

Authors:  Stephen S Whitehead
Journal:  Expert Rev Vaccines       Date:  2015-12-02       Impact factor: 5.217

9.  Asymptomatic humans transmit dengue virus to mosquitoes.

Authors:  Veasna Duong; Louis Lambrechts; Richard E Paul; Sowath Ly; Rath Srey Lay; Kanya C Long; Rekol Huy; Arnaud Tarantola; Thomas W Scott; Anavaj Sakuntabhai; Philippe Buchy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-09       Impact factor: 11.205

10.  Autochthonous dengue fever, Tokyo, Japan, 2014.

Authors:  Satoshi Kutsuna; Yasuyuki Kato; Meng Ling Moi; Akira Kotaki; Masayuki Ota; Koh Shinohara; Tetsuro Kobayashi; Kei Yamamoto; Yoshihiro Fujiya; Momoko Mawatari; Tastuya Sato; Junwa Kunimatsu; Nozomi Takeshita; Kayoko Hayakawa; Shuzo Kanagawa; Tomohiko Takasaki; Norio Ohmagari
Journal:  Emerg Infect Dis       Date:  2015-03       Impact factor: 6.883
View more
  2 in total

Review 1.  Dengue-associated hemophagocytic lymphohistiocytosis in an adult: A case report and literature review.

Authors:  Sang Mi Chung; Joon Young Song; Wonshik Kim; Min Joo Choi; Ji Ho Jeon; Seonghui Kang; Eunju Jung; Ji Yun Noh; Hee Jin Cheong; Woo Joo Kim
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.817

2.  Efficient Delivery of Dengue Virus Subunit Vaccines to the Skin by Microprojection Arrays.

Authors:  David A Muller; Alexandra C I Depelsenaire; Ashleigh E Shannon; Daniel Watterson; Simon R Corrie; Nick S Owens; Christiana Agyei-Yeboah; Stacey T M Cheung; Jin Zhang; Germain J P Fernando; Mark A F Kendall; Paul R Young
Journal:  Vaccines (Basel)       Date:  2019-11-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.